Chiudi menu
Group
Companies
History
Mission, Vision and Values
Business model
Innovation
Scientific research
Quality and certifications
Investor Relations
Share Capital and Shareholding
Stock performance
Stock Market Research and Studies
Brokers and SDIR
Financial statements and reports
Company profile
Presentations
Corporate Events
Euronext Milan Prospectus
Governance
Code of ethics and policies
Model 231
Intro to Special Section Model 231
Whistleblowing Reports
BOD and Committees
Statutory auditors and Audit firm
Shareholders’ Meeting
Company Documents
Internal Dealing
Sharholders Agreements
Sustainability
ESG PLAN AND SUSTAINABILITY REPORTS
SOCIAL COMMITMENT
Company Welfare
Our commitment to Sport
Careers
Media
Press releases
Press reviews
News
Chiudi ricerca
it
en
Group
Companies
History
Mission, Vision and Values
Business model
Innovation
Scientific research
Quality and certifications
Investor Relations
Share Capital and Shareholding
Stock performance
Stock Market Research and Studies
Brokers and SDIR
Financial statements and reports
Company profile
Presentations
Corporate Events
Euronext Milan Prospectus
Governance
Code of ethics and policies
Model 231
Intro to Special Section Model 231
Whistleblowing Reports
BOD and Committees
Statutory auditors and Audit firm
Shareholders’ Meeting
Company Documents
Internal Dealing
Sharholders Agreements
Sustainability
ESG PLAN AND SUSTAINABILITY REPORTS
SOCIAL COMMITMENT
Company Welfare
Our commitment to Sport
Careers
Media
Press releases
Press reviews
News
News
PHARMANUTRA S.P.A. ALONGSIDE “AF CORSE,” FERRARI HYPERCAR’S RACING PARTNER
FILING OF DOCUMENTS FOR THE SHAREHOLDERS’ MEETING
BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31.12.2025
Pharmanutra obtains FDA registration for its Pisa manufacturing facility
DISTRIBUTION OF SIDERAL® PRODUCTS IN FRANCE AND SWITZERLAND
APPROVAL OF THE BOARD OF DIRECTORS GUIDELINES AND APPOINTMENT OF THE INVESTOR RELATIONS DIRECTOR
PHARMANUTRA S.P.A. OBTAINS ISO 13485 CERTIFICATION
Pharmanutra strengthens its commitment to elite sport: agreement with Lorenzo Musetti, new Cetilar® Nutrition Ambassador
SOLID DOUBLE-DIGIT REVENUE GROWTH IN 2025 DRIVEN BY STRONG CONTRIBUTION FROM INTERNATIONAL MARKETS AND NEW BUSINESS UNITS
PUBLICATION OF THE 2026 CORPORATE EVENTS CALENDAR
Pharmanutra accelerates international expansion in the Far East through the Alibaba ecosystem
Cetilar® Nutrition confirmed as Official Nutrition Partner of the 2026 Giro d’Italia
PHARMANUTRA S.P.A. LISTED AMONG THE WORLD’S BEST COMPANIES FOR SUSTAINABLE GROWTH BY “TIME” MAGAZINE
BOARD OF DIRECTORS APPROVES THE INTERIM MANANGEMENT REPORT AS OF SEPTEMBER 30, 2025
MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUERS SECURITIES
Pharmanutra awards ten graduation prizes to young graduates of the University of Parma
SIDERAL® FORTE AWARDED BEST NUTRACEUTICAL PRODUCT AT SPAZIO NUTRIZIONE
INITIATION OF SHARE BUY-BACK PROGRAM
BOARD OF DIRECTORS APPROVES THE HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2025
Pharmanutra at GOAL! Festival 2025: ethics, health and sports culture
Loading...